Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants

In 2019, five million deaths associated with antimicrobial resistance were reported by The Centers for Disease Control and Prevention (CDC). <i>Acinetobacter baumannii</i>, a Gram-negative bacterial pathogen, is among the list of urgent threats. Previously, we reported 2-aminoimidazole (...

Full description

Bibliographic Details
Main Authors: Ashley N. Crotteau, Veronica B. Hubble, Santiana A. Marrujo, Anne E. Mattingly, Roberta J. Melander, Christian Melander
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/12/11/1563
_version_ 1797460415755583488
author Ashley N. Crotteau
Veronica B. Hubble
Santiana A. Marrujo
Anne E. Mattingly
Roberta J. Melander
Christian Melander
author_facet Ashley N. Crotteau
Veronica B. Hubble
Santiana A. Marrujo
Anne E. Mattingly
Roberta J. Melander
Christian Melander
author_sort Ashley N. Crotteau
collection DOAJ
description In 2019, five million deaths associated with antimicrobial resistance were reported by The Centers for Disease Control and Prevention (CDC). <i>Acinetobacter baumannii</i>, a Gram-negative bacterial pathogen, is among the list of urgent threats. Previously, we reported 2-aminoimidazole (2-AI) adjuvants that potentiate macrolide activity against <i>A. baumannii</i>. In this study, we identify several of these adjuvants that sensitize <i>A. baumannii</i> to aminoglycoside antibiotics. Lead compounds <b>1</b> and <b>7</b> lower the tobramycin (TOB) minimum inhibitory concentration (MIC) against the TOB-resistant strain AB5075 from 128 μg/mL to 2 μg/mL at 30 μM. In addition, the lead compounds lower the TOB MIC against the TOB-susceptible strain AB19606 from 4 μg/mL to 1 μg/mL and 0.5 μg/mL, respectively, at 30 μM and 15 μM. The evolution of resistance to TOB and <b>1</b> in AB5075 revealed mutations in genes related to protein synthesis, the survival of bacteria under environmental stressors, bacteriophages, and proteins containing Ig-like domains.
first_indexed 2024-03-09T17:05:41Z
format Article
id doaj.art-aae56fb03b6846dc8796944a36dc7b9d
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-09T17:05:41Z
publishDate 2023-10-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-aae56fb03b6846dc8796944a36dc7b9d2023-11-24T14:25:07ZengMDPI AGAntibiotics2079-63822023-10-011211156310.3390/antibiotics12111563Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole AdjuvantsAshley N. Crotteau0Veronica B. Hubble1Santiana A. Marrujo2Anne E. Mattingly3Roberta J. Melander4Christian Melander5Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USADepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USADepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USADepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USADepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USADepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USAIn 2019, five million deaths associated with antimicrobial resistance were reported by The Centers for Disease Control and Prevention (CDC). <i>Acinetobacter baumannii</i>, a Gram-negative bacterial pathogen, is among the list of urgent threats. Previously, we reported 2-aminoimidazole (2-AI) adjuvants that potentiate macrolide activity against <i>A. baumannii</i>. In this study, we identify several of these adjuvants that sensitize <i>A. baumannii</i> to aminoglycoside antibiotics. Lead compounds <b>1</b> and <b>7</b> lower the tobramycin (TOB) minimum inhibitory concentration (MIC) against the TOB-resistant strain AB5075 from 128 μg/mL to 2 μg/mL at 30 μM. In addition, the lead compounds lower the TOB MIC against the TOB-susceptible strain AB19606 from 4 μg/mL to 1 μg/mL and 0.5 μg/mL, respectively, at 30 μM and 15 μM. The evolution of resistance to TOB and <b>1</b> in AB5075 revealed mutations in genes related to protein synthesis, the survival of bacteria under environmental stressors, bacteriophages, and proteins containing Ig-like domains.https://www.mdpi.com/2079-6382/12/11/1563<i>Acinetobacter baumannii</i>antibiotic resistanceaminoglycosidesantibiotic adjuvant
spellingShingle Ashley N. Crotteau
Veronica B. Hubble
Santiana A. Marrujo
Anne E. Mattingly
Roberta J. Melander
Christian Melander
Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
Antibiotics
<i>Acinetobacter baumannii</i>
antibiotic resistance
aminoglycosides
antibiotic adjuvant
title Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
title_full Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
title_fullStr Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
title_full_unstemmed Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
title_short Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
title_sort sensitization of gram negative bacteria to aminoglycosides with 2 aminoimidazole adjuvants
topic <i>Acinetobacter baumannii</i>
antibiotic resistance
aminoglycosides
antibiotic adjuvant
url https://www.mdpi.com/2079-6382/12/11/1563
work_keys_str_mv AT ashleyncrotteau sensitizationofgramnegativebacteriatoaminoglycosideswith2aminoimidazoleadjuvants
AT veronicabhubble sensitizationofgramnegativebacteriatoaminoglycosideswith2aminoimidazoleadjuvants
AT santianaamarrujo sensitizationofgramnegativebacteriatoaminoglycosideswith2aminoimidazoleadjuvants
AT anneemattingly sensitizationofgramnegativebacteriatoaminoglycosideswith2aminoimidazoleadjuvants
AT robertajmelander sensitizationofgramnegativebacteriatoaminoglycosideswith2aminoimidazoleadjuvants
AT christianmelander sensitizationofgramnegativebacteriatoaminoglycosideswith2aminoimidazoleadjuvants